OpenAI acquires Ashoka Rajendra’s Orchestra Bio
OpenAI has bought Orchestra Bio, a company started by Indian American technology entrepreneur Ashoka Rajendra. Orchestra Bio helps biotechnology and drug companies organize the many complicated steps involved in developing new medicines.
On Tuesday, OpenAI announced that it was bringing Orchestra Bio's team and technology together with Rosalind, its AI models and tools for life sciences research. The goal is to help scientists make new discoveries and manage the work needed to turn those discoveries into treatments that patients can receive sooner.
Rajendra said on X that he started Orchestra Bio four years ago to help biotechnology and pharmaceutical companies move their drug development projects forward.
He said the team was excited that Orchestra Bio was joining OpenAI, where it could continue working toward the same goal on a much larger scale.
The companies did not share how much OpenAI paid for Orchestra Bio. However, reports say the startup had raised about $20 million from investors by 2025. These investors included Andreessen Horowitz, Atria, and 8VC.
Rajendra explained that developing medicines is extremely complicated. It involves thousands of decisions and tasks that depend on one another. These steps include discovering possible medicines, testing them before human trials, manufacturing them, and testing them in clinical studies involving people.
He said AI has now reached an important turning point where people and AI agents can work together on these challenges. AI agents can help make plans, organize tasks, and study information. This allows scientists and project leaders to spend more time making important decisions that need their special knowledge and experience.
OpenAI said Orchestra Bio's employees and technology will help develop Rosalind, its AI model for life sciences research. They will also work on Rosalind Workbench, a tool designed to help researchers plan experiments and study their results.
OpenAI says some major companies are already using Rosalind. According to OpenAI, these customers include Moderna and Novo Nordisk.
Rosalind gives researchers who study living things access to AI models and tools. OpenAI explained that GPT-Rosalind helps scientists think through difficult questions about biology and chemistry. Rosalind Workbench connects these AI abilities with scientific tools and data, helping researchers understand experiment results and plan what to test next.
Orchestra Bio brings employees with experience in biotechnology, software, and artificial intelligence. It also brings a technology platform designed to help teams organize the work involved in developing medicines.
OpenAI said the two teams want to build AI agents that help researchers connect scientific discoveries with the studies, decisions, and next steps needed to turn a possible new medicine into a treatment.